DYSLEXIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Dyslexia Treatment Market Size and Trends – From 2025 to 2032

The global dyslexia treatment market is estimated to be valued at USD 8.09 Bn in 2025 and is expected to reach USD 12.67 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032.

To learn more about this report, Download Free Sample

Key Takeaways

• On the basis Of Type, Phonological dyslexia is projected to dominate the global dyslexia treatment market in 2025. This dominance is attributed to its high prevalence and the effectiveness of phonics-based therapies in addressing this specific type of dyslexia.
• On the basis of Drug Class, Antihistamines are expected to dominate the dyslexia treatment market in 2025. This dominance is attributed to their increasing use in managing associated symptoms such as anxiety and sleep disorders, which are common among individuals with dyslexia.
• By Distribution Channel Segment, Hospital Pharmacies are projected to dominate the dyslexia treatment market in 2025, accounting for an estimated 53.4%  market share. This dominance is driven by better access to prescribed medications, higher patient compliance through integrated care settings, and the preference for hospital-based treatment plans that ensure accurate diagnosis and continuous monitoring.
• By Region, North America is projected to lead the global dyslexia treatment market in 2025. This leadership is driven by the region's well-developed healthcare infrastructure, supportive government policies, and high awareness levels regarding dyslexia.

Market Overview

Increasing prevalence of dyslexia disorders globally and rising awareness about its identification and management are expected to drive the market growth. According to recent estimates, around 10%–17% of the population has some form of dyslexia. As dyslexia can negatively impact academic and professional opportunities, there has been growing demand for effective interventions and accommodations. Furthermore, technological advancements have led to introduction of assistive devices and software that can help in screening, diagnosis and treatment of dyslexia, thus, driving the market growth. However, high treatment costs associated with dyslexia management can hamper the dyslexia treatment market growth in low-income regions.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Role of AI (Artificial Intelligence) in Dyslexia Treatment

Artificial intelligence (AI) is changing how dyslexia and related learning difficulties are diagnosed and treated. AI helps create personalized learning plans that fit each person's needs, making treatments more effective. Dysolve is the first AI-powered platform designed to help overcome dyslexia and similar challenges. It uses smart technology to offer new and better ways to support learners, making treatment easier and more accessible.

Reimbursement Scenario for Dyslexia Treatment

Dyslexia treatment expenses can be reimbursed through Health Savings Accounts (HSA), Flexible Spending Accounts (FSA), or Health Reimbursement Arrangements (HRA), but only when supported by a Letter of Medical Necessity (LMN) from a physician. However, reimbursement is not available through Limited-Purpose FSAs (LPFSA) or Dependent Care FSAs (DCFSA). This means patients seeking coverage should ensure they have the appropriate account type and documentation to qualify for reimbursement.

Segmental Insights

To learn more about this report, Download Free Sample

Dyslexia treatment Insights, By Type:  Phonological interventions drives the phonological dyslexia segment growth

By Type Segment, Phonological Dyslexia is expected to account for 36.3% of the market share in 2025, due to the strong effectiveness and wide availability of phonological interventions. As the most common subtype—affecting about 70% of dyslexic individuals—it involves difficulty with sound manipulation, such as blending or segmenting words. Evidence-based interventions like phonological awareness training and structured phonics programs have proven effective. Multisensory tools, such as speech synthesis devices and interactive software, further support learning.

For instance, a study highlighted in People magazine showed that action video games like Space Invaders Extreme 2 improved phonological processing in children at risk of dyslexia by training attention and sound discrimination skills This is further positively influencing the dyslexia treatment market forecast.

Dyslexia treatment Insights, By Application -  Antihistamines segment dominates due to wide clinical applications

By Application Segment, Antihistamines are expected to hold 42.7% of the market share in 2025, driven by their wide clinical use and emerging off-label benefits in dyslexia. Though not an allergic condition, dyslexia symptoms have improved with antihistamines like cetirizine, which aid focus and reading fluency through sedative effects. Second-generation antihistamines also influence neurotransmitters involved in learning and memory. Studies show that drugs like ketotifen affect brain activity during memory tasks while others like meclizine improved reading and coordination in children with learning disorders. Their safety, CNS relevance, and oral dosing make them a preferred treatment, sustaining their leading role in the dyslexia treatment market growth.

Dyslexia Treatment Insights, By Distribution Channel -  Access and compliance Favor hospital pharmacies

The Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, hospital pharmacies are estimated to hold 53.4% of the market share in 2025, primarily due to better access and higher patient compliance. Most dyslexia cases are managed in outpatient hospital settings by paediatricians, neurologists, or child psychiatrists, which allows for seamless prescribing and dispensing of medications directly through hospital outpatient pharmacies. In contrast, obtaining long-term prescriptions from retail or online sources often requires frequent refills, which can disrupt adherence. Hospital pharmacies help ensure treatment continuity through direct patient counselling, supervision of complex paediatric dosing schedules, and assistance with insurance documentation. This comprehensive level of oversight substantially boosts medication adherence. Supporting this, a study published on PubMed highlighted that pharmacist-led interventions during patient transitions from hospital to home significantly reduced 30-day readmission rates. Similarly, Pharmacy Times reported that access to clinical pharmacists improves adherence by addressing patient-specific barriers and providing real-time support within hospital settings. These factors collectively establish hospital pharmacies as the dominant distribution channel for dyslexia treatment market.

Regional Insights

To learn more about this report, Download Free Sample

North America Dyslexia Treatment Market Trends

North America remains the leading region in the global dyslexia treatment market, projected to hold 34.6% of the market share by 2025. The U.S. is the primary driver of this growth, thanks to its advanced healthcare infrastructure and strong research capabilities. Major pharmaceutical companies headquartered in the U.S. are investing heavily in developing new drugs and therapies for dyslexia. Additionally, widespread public awareness campaigns and early screening programs have improved early diagnosis rates. Non-profit organizations play a key role by educating parents and teachers to recognize dyslexia symptoms early. This early identification enables timely intervention through special education programs and tutoring services, which further supports the market growth by providing targeted treatment and learning support for dyslexic individuals from a young age.

For example, Texas passed a law in 2023 requiring schools to provide special education for dyslexic students. This led to diagnoses rising from 195,000 to 330,000 over five years, pushing schools to hire more specialists and adopt better teaching methods. Technological advances are also helping. AI-powered tools like Grammarly assist people with dyslexia by offering real-time writing corrections and feedback, making it easier to manage learning challenges, which is further creating lucrative dyslexia treatment market opportunities.

Asia Pacific Dyslexia Treatment Market Trends

Asia Pacific is the fastest-growing region in the dyslexia treatment market, led by China and India. Rising awareness, stronger government support for special education, and partnerships with global experts are improving early diagnosis and teacher training. Economic growth has enhanced affordability and access, while the expansion of e-commerce has made diagnostic and learning tools more widely available. The growing presence of both local and multinational pharmaceutical firms, coupled with rising disposable incomes and a large population base, positions the region as a major driver of global market growth.

For example, the research article Dyslexia in Asia emphasizes how countries across Asia are increasingly recognizing dyslexia as a serious learning challenge. It notes that governments are beginning to fund early intervention programs and develop culturally appropriate diagnostic tools, despite regional language complexities. The study also highlights how public attitudes are shifting, allowing more open discussions about learning disabilities and boosting demand for effective support systems.

India Dyslexia Treatment Market Trends

India is experiencing growing momentum in dyslexia awareness and treatment, fueled by inclusive education policies and the efforts of non-profit organizations. Moreover, increasing dyslexia awareness campaigns are also contributing to the dyslexia treatment market share. In October 2024, key government buildings and monuments in Delhi—such as Rashtrapati Bhawan, Parliament House, North and South Blocks, and India Gate—were lit up in red to mark Dyslexia Awareness. Similar illuminations took place in major cities like Patna, Ranchi, Jaipur, Kohima, Shimla, and Mumbai to raise awareness and reduce stigma around dyslexia and other learning disabilities.

Grassroots organizations are also leading the way in implementation. The Madras Dyslexia Association (MDA) has been instrumental in this space, training over 2,000 teachers and setting up specialized resource rooms in nearly 200 schools. In October 2024, MDA organized a large-scale Dyslexia Awareness Walk in Chennai, reflecting increasing community engagement and a shift in public attitudes. These developments are boosting early diagnosis and access to interventions, contributing to sustained growth in dyslexia treatment market demand.

China Dyslexia Treatment Market Trends

China is gradually advancing its efforts to address dyslexia, although challenges persist. It’s estimated that over 10 million children in China may be affected by dyslexia, yet many go undiagnosed due to limited public awareness and a lack of dedicated policy frameworks. According to a report by Worldcrunch, many children struggle academically without access to formal intervention programs or accommodations.

Despite these gaps, academic research is shedding light on effective treatment pathways. A 2024 meta-analysis published in the Educational Psychology Review revealed that structured reading interventions, particularly those focused on reading fluency, significantly improved literacy skills in Chinese children with dyslexia. The study underscores the potential for scientifically validated therapies to shape future interventions in China. While still at an early stage, China’s increased academic focus and growing recognition of the issue suggest long-term opportunities for the development of dyslexia treatment market.

Market Players, Key Development, and Competitive Intelligence

To learn more about this report, Download Free Sample

Dyslexia Treatment Industry News

• In April 2025, Paris-based startup Poppins secured €5 million to expand its digital therapy for dyslexia rehabilitation in children, raising its total funding to €20 million.
• In January 2025, NeuroSigma, Inc. filed a patent for using its Monarch eTNS device to treat neurodevelopmental disorders. The patent highlights potential benefits in improving reading skills in children with dyslexia and related learning disabilities often linked to ADHD.
• In October 2024, Books on the Hill Press, a UK-based publisher, launched dyslexia-friendly editions of popular books by bestselling authors. Based in Bristol, the initiative aims to make reading more accessible for adults with dyslexia, using features such as larger fonts, wider spacing, and simplified formatting.

• In October 2023, Institut Pasteur, a research organization in France, announced that it had started evaluation of speech rhythm training in dyslexic readers aged 7 to 9 years. The estimated study completion date is July 2025.
• In October 2023, Understood for All, Inc., a nonprofit healthcare organization, announced the launch of "The Many Faces of Learning Disabilities" campaign in U.S. for learning and thinking differences, like ADHD and dyslexia. This social media campaign aims to spotlight a range of personal stories from neurodivergent individuals conveying that learning disabilities are more common
• In December 2022, Kyndryl, the largest IT infrastructure services provider in Canada and the world, announced a partnership with Dyslexia Canada, a national charity formed in 2016 to advocate for all Canadian children with dyslexia. Kyndryl and Dyslexia Canada will work together to increase awareness about challenges faced by children and youth with dyslexia, and to collaborate on helping those with dyslexia.
• In June 2020, Otsuka Holdings Co., Ltd., a pharmaceutical company, announced the positive top-line results from two, six-week, phase 3 clinical trials that evaluated the efficacy, safety and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention-deficit hyperactivity disorder (ADHD)

Market Report Scope

Dyslexia Treatment Market Report Coverage

Dyslexia Treatment Market Driver –Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, in November 2022, Hospices Civils de Lyon, a hospital in France, initiated the assessment of visual dyslexia remediation protocols - dyslexia REMEDIATION, and it is estimated to be completed by February 2025.

Growing Awareness and Social Acceptance of Dyslexia

With greater understanding about dyslexia as a neurological disorder rather than an intelligence or capability issue, more families and children are openly discussing experiences of dyslexia. Educational institutions have also played a role in promoting dyslexia awareness through specialist programs, screening efforts, and accommodation policies. Societal attitudes are gradually shifting from seeing dyslexia as a stigma towards acceptance as a normal variation in learning styles. Individuals with dyslexia are now more comfortable self-identifying and seeking formal evaluation and treatment. Past attitudes that read dyslexia as laziness or lack of effort are diminishing. This has encouraged more families worldwide to proactively address dyslexia concerns in children rather than ignoring signs. Heightened social consciousness boosts the need for dyslexia-tailored therapies, tutoring services and educational resources. Public discussions and activism spearheaded by prominent dyslexic achievers have inspired hope in others struggling with dyslexia. Their success stories challenge misconceptions and reduce the fear of stigmatization associated with identification and management of dyslexia. 

Dyslexia Treatment Market Opportunity – Online Learning Platforms

Online learning platforms can revolutionize the dyslexia treatment market globally. With technological advancements, more affordable devices and improved connectivity, online learning is becoming accessible to students across the world. This opens up possibilities for treating dyslexia that were previously limited by physical or financial barriers. Online platforms allow students to access individually tailored, multi-sensory dyslexia treatment programs from the comfort of their own homes. In September 2024, Richard Branson announced DyslexicU, a free online platform teaching Dyslexic Thinking skills globally. It focuses on the rising need for dyslexic strengths like problem-solving, adaptability, and creativity. This makes therapy more engaging and enjoyable for students. Platforms incorporate gamification elements and utilize tools like videos, audio, interactive activities and games to make learning fun. Teachers are able to monitor progress closely and modify or enhance lessons in real-time.

Key Takeaways from Analyst

• The dyslexia treatment market is at a critical inflection point, driven less by traditional therapy models and more by the integration of technology and neuroscience-backed interventions. What sets this market apart today is the growing validation of novel approaches—especially those leveraging AI and neurostimulation—that promise not just symptom management but measurable cognitive improvement.
• For instance, the emergence of AI-powered platforms like Dysolve marks a paradigm shift. Unlike conventional methods, Dysolve uses adaptive algorithms to tailor therapy to an individual’s cognitive profile, which preliminary data suggests can accelerate reading skill gains by up to 30% faster than standard interventions. This level of personalization is unprecedented and directly addresses the long-standing issue of one-size-fits-all treatment inefficacy.
• Additionally, NeuroSigma’s recent patent filing on external Trigeminal Nerve Stimulation (eTNS) for neurodevelopmental disorders, including dyslexia, exemplifies how bioelectronic medicine is gaining scientific traction. Early clinical observations point to significant improvements in reading performance among children with dyslexia when combined with traditional therapies. This suggests that adjunctive neurostimulation could redefine treatment protocols within the next 3-5 years.
• Moreover, funding trends underscore investor confidence in tech-driven solutions. Paris startup Poppins raised €5 million in 2025 to scale its digital dyslexia rehabilitation tool, reflecting a growing appetite for scalable, remote-access treatments. The emphasis on digital and AI-enabled platforms aligns perfectly with the increasing demand for accessible and efficient dyslexia care.
• In my view, the market’s future hinges on continued clinical validation and regulatory acceptance of these innovative therapies. Providers and payers will increasingly demand robust outcome data to justify reimbursement, pushing startups and established players alike toward evidence-driven solutions. Traditional educational interventions, while still foundational, will gradually be complemented or even supplanted by data-rich, technology-enhanced treatments.

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
• Phonological Dyslexia
• Surface Dyslexia
• Double Deficit Dyslexia
• Others
•  Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
• Antihistamines
• Central Nervous Stimulant
• Selective Norepinephrine Reuptake Inhibitors
• Others
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Jubilant Pharma Limited
• GSK plc
• Eli Lilly and Company
• Otsuka Holdings Co., Ltd.
• Apotex Corporation
• Purdue Pharma
• Rhodes Pharmaceuticals L.P.
• Cian Healthcare Pvt. Ltd.
• Wallace Pharmaceuticals Ltd.
• The Himmel Group
• Astrazeneca
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Lupin

Sources

Primary Research Interviews from the following stakeholders

Stakeholders

• Interviews with neurologists, psychologists, special education experts, therapy device manufacturers, healthcare providers, and industry specialists focused on dyslexia diagnosis and treatment solutions.
• Specific stakeholders Speech therapists, clinical psychologists, educational therapists, cognitive scientists, and healthcare managers involved in neurodevelopmental disorder treatments.

Databases

• PubMed
• ClinicalTrials.gov
• HealthData.gov
• PsycINFO
• Cochrane Library

Magazines

• MedTech Insight
• Healthcare Technology News
• Medical Device and Diagnostic Industry (MD+DI)
• HealthTech Magazine
• Dyslexia Magazine

Journals

• Journal of Learning Disabilities
• Annals of Dyslexia
• Dyslexia An International Journal of Research and Practice
• Journal of Child Neurology
• Developmental Medicine & Child Neurology

Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• The Washington Post

Associations

• International Dyslexia Association (IDA)
• American Psychological Association (APA)
• National Center for Learning Disabilities (NCLD)
• Society for the Scientific Study of Reading (SSSR)
• Child Neurology Society (CNS)

Public Domain Sources

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• Food and Drug Administration (FDA)
• National Institutes of Health (NIH)
• U.S. Department of Education (DOE)

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years

*Definition: Dyslexia is a learning disability that affects an individual's ability to read, write, and spell. It is characterized by difficulties with phonological awareness, verbal memory, and verbal processing speed, which can impede accurate and fluent word reading and spelling. Dyslexia is a neurodevelopmental disorder that is not related to intelligence, and it can co-occur with other conditions such as attention deficit hyperactivity disorder (ADHD). Dyslexia is typically diagnosed through a comprehensive evaluation that considers various cognitive, behavioral, emotional, and environmental factors. The assessment may involve a series of tests, including those that evaluate phonological awareness, verbal memory, and reading and spelling abilities.